Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

RXL vs JDOC overlap: 51% of top holdings shared

Bottom line

How much do RXL and JDOC overlap?

51% of their top holdings overlap by weight. 12 securities appear in both funds' top 25, making up 48.9% of RXL's assets and 50.7% of JDOC's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

RXLJDOC
Weight overlap (top 25)51%
Shared holdings12
Weight in shared holdings48.9%50.7%
Total positions7061
Expense ratio0.95%0.65%
Holdings as ofMay 31, 2026Jul 31, 2026

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Holdings RXL and JDOC have in common

Holding% of RXL% of JDOCOverlap
Eli Lilly & Co.12.67%7.76%7.76%
Johnson & Johnson7.86%4.82%4.82%
AbbVie, Inc.5.57%7.85%5.57%
UnitedHealth Group, Inc.4.98%5.85%4.98%
Merck & Co., Inc.4.26%4.82%4.26%
Thermo Fisher Scientific, Inc.2.68%3.73%2.68%
Intuitive Surgical, Inc.2.18%1.93%1.93%
Abbott Laboratories2.15%3.11%2.15%
Bristol-Myers Squibb Co.1.68%3.57%1.68%
CVS Health Corp.1.67%2.83%1.67%
Danaher Corp.1.66%2.16%1.66%
Stryker Corp.1.52%2.23%1.52%

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in RXL

  1. ProShares GENIUS Money Market ETF — 11.81%
  2. Repurchase Agreement — 2.91%
  3. Amgen, Inc. — 2.62%
  4. Gilead Sciences, Inc. — 2.41%
  5. Pfizer, Inc. — 2.15%
  6. Repurchase Agreement — 1.83%
  7. Vertex Pharmaceuticals, Inc. — 1.64%
  8. Repurchase Agreement — 1.37%
  9. Medtronic plc — 1.37%
  10. McKesson Corp. — 1.32%
  11. Elevance Health, Inc. — 1.26%
  12. Cigna Group (The) — 1.06%
  13. Boston Scientific Corp. — 1.04%

Only in JDOC

  1. AstraZeneca plc — 3.76%
  2. Roche Holding AG — 2.82%
  3. Novo Nordisk A/S — 2.61%
  4. GSK plc — 2.47%
  5. Cencora, Inc. — 2.07%
  6. Argenx SE — 2.06%
  7. Edwards Lifesciences Corp. — 1.73%
  8. IQVIA Holdings, Inc. — 1.71%
  9. Teva Pharmaceutical Industries Ltd. — 1.60%
  10. Regeneron Pharmaceuticals, Inc. — 1.60%
  11. Novartis AG — 1.60%
  12. Biogen, Inc. — 1.56%
  13. Cardinal Health, Inc. — 1.51%

Asset mix

Asset typeRXLJDOC
Stocks78.0%99.2%
Other11.8%—
Repurchase agreements7.1%—

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Country mix

CountryRXLJDOC
US85.6%75.2%
GB—6.2%
CH—4.4%
DK—4.0%
JP—2.5%
NL—2.4%
DE—1.9%
IE1.7%0.4%

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Check another pair

FAQ

How much do RXL and JDOC overlap?
About 51% by weight. 12 securities appear in both funds' top 25 holdings; they make up 48.9% of RXL's assets and 50.7% of JDOC's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do RXL and JDOC have in common?
The largest shared holdings are Eli Lilly & Co., AbbVie, Inc., UnitedHealth Group, Inc., Johnson & Johnson, Merck & Co., Inc..
Should I own both RXL and JDOC?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, RXL or JDOC?
RXL is broader, with 70 positions versus 61 for JDOC. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.